Drug intelligence / Profile preview

pediococcus acidilactici CECT7483

Development stage: Unknown
Lead developer: AB-BIOTICS
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Pediococcus acidilactici CECT7483 is a specific probiotic bacterial strain developed by AB-Biotics SA. It is primarily utilized as a key component of the multi-strain probiotic formulation EQBIOTA, alongside Lactiplantibacillus plantarum strains CECT7484 and CECT7485. Deposited in the Spanish Type Culture Collection in 2009, this strain is indicated for the management of gastrointestinal conditions, including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and functional gastrointestinal disorders. Its mechanism of action involves modulating the gut microbiota, enhancing intestinal barrier function, and producing beneficial metabolites such as indole derivatives, which contribute to reduced intestinal inflammation and permeability. It is marketed as a food supplement and is typically administered orally in capsule form.

Other names: Pediococcus acidilactici CECT 7483

Beyond the preview

Go deeper on pediococcus acidilactici CECT7483.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pediococcus acidilactici CECT7483.

Explore the full profile